Department of Gastroenterology and Hepatology, Graduate School of Medicine, Yamaguchi University, Ube, Japan.
Hepatol Res. 2007 Aug;37(8):608-14. doi: 10.1111/j.1872-034X.2007.00036.x. Epub 2007 May 22.
We have reported that one-week administration of a late evening snack (LES) improved not only malnutrition but also glucose intolerance in hospitalized patients with liver cirrhosis. Thus, we investigated whether long-term LES administration to outpatients for 3 months could reproduce the results obtained from hospitalized patients, especially improved glucose intolerance. If this treatment aggravated glucose intolerance, we tried to find any marker predicting this aggravation before the treatment.
Outpatients were prescribed one pack of oral supplementation of a branched-chain amino acid (BCAA)-enriched nutrient, Aminoleban EN (210 kCal) as a LES without dietician supervision. Both before LES administration and after 3 months, glucose tolerance and liver function were examined using a 75 g oral glucose tolerance test (OGTT), biochemical parameters in blood and the relationship between glucose tolerance (area under the curve (AUC)) and the following serum markers.
Branched-chain amino acid/tyrosine ratio (BTR), the number of red blood cells (RBC), and hematocrit (Ht) significantly increased, with significant reduction of blood NH(3) level in patients with a blood glucose level less than 200 mg/dL 2 h after 75 g OGTT. However, the increase of AUC was seen after 3 months of LES administration in patients who had blood glucose higher than 200 mg/dL 2 h after 75 g OGTT. AUC weakly correlated positively with serum 7S collagen and negatively with choline esterase (ChE) and albumin (Alb).
75 g OGTT is a useful marker to predict the worst outcome and avoid the adverse effect of LES treatment in liver cirrhosis patients if performed without adequate nutrient conduct by a dietician.
我们曾报道,在肝硬化住院患者中,一周一次的晚间点心(LES)治疗不仅能改善营养不良,还能改善葡萄糖耐量受损。因此,我们研究了门诊患者长期(3 个月)LES 治疗是否能再现住院患者的结果,尤其是改善葡萄糖耐量受损。如果这种治疗加重了葡萄糖耐量受损,我们试图在治疗前找到任何预测这种加重的标志物。
为门诊患者开了一包富含支链氨基酸(BCAA)的口服补充剂 Aminoleban EN(210kcal)作为 LES,无需营养师监督。在开始 LES 治疗前和 3 个月后,通过 75g 口服葡萄糖耐量试验(OGTT)检查葡萄糖耐量和肝功能,检测血液生化参数以及葡萄糖耐量(曲线下面积(AUC))与以下血清标志物之间的关系。
2 小时后血糖水平<200mg/dL 的患者,支链氨基酸/酪氨酸比值(BTR)、红细胞(RBC)数量和红细胞压积(Ht)显著增加,血液氨(NH3)水平显著降低。然而,2 小时后血糖水平>200mg/dL 的患者在接受 LES 治疗 3 个月后,AUC 增加。AUC 与血清 7S 胶原呈弱正相关,与胆碱酯酶(ChE)和白蛋白(Alb)呈负相关。
如果由营养师进行适当的营养指导,75g OGTT 是一种有用的标志物,可以预测肝硬化患者的最差结果,并避免 LES 治疗的不良反应。